US › Healthcare

Anika Therapeutics Inc (ANIK)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$19.61-5.43%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$32.6M
Revenue YoY
+15.6%
Net profit
$3.3M
Profit YoY
+183.4%
EPS
$0.30
EPS estimate
$-0.19
Net margin
10.1%

EPS came in at 0.30 against a street estimate of -0.19 — a beat of 257.9%.

Key statistics

Market cap
$258.0M
Forward P/E
49.5
P/B
1.88
Book value
$10.03
EPS (TTM)
$-0.23
52-week high
$21.11
52-week low
$7.92
50-day MA
$15.16
200-day MA
$12.52
Beta
0.23

Analyst view

Analysts rate Anika Therapeutics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $21.00.

Shareholding

Insiders
6.39%
Institutions
94.35%

Largest institutional holders

FundStake
BlackRock Inc11.92%
Caligan Partners LP10.72%
Morgan Stanley - Brokerage Accounts6.52%
Acadian Asset Management LLC4.53%
Vanguard Capital Management, LLC4.53%
BOOTHBAY FUND MANAGEMENT, LLC3.96%
Renaissance Technologies Corp3.75%
Dimensional Fund Advisors, Inc.3.43%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Anika Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.